Nasal Corticosteroids Market Report 2025

The nasal corticosteroids market size has grown strongly in recent years. It will grow from $6.19 billion in 2024 to $6.7 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The expansion during the historical period is driven by greater awareness of nasal corticosteroid therapies, a rising number of chronic sinusitis cases, increased use of over-the-counter nasal sprays, heightened emphasis on outpatient care, and wider availability of generic products.

The nasal corticosteroids market size is expected to see strong growth in the next few years. It will grow to $9.14 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The projected growth during the forecast period is fueled by an increasing emphasis on non-invasive drug delivery methods, rising investments in intranasal drug development, improved healthcare access in developing regions, growing demand for combination nasal treatments, and expanding e-commerce channels for nasal medications. Key trends expected in this period include advancements in intranasal delivery technologies, enhanced formulations of combination therapies, the introduction of over-the-counter nasal corticosteroids, innovations in pediatric-friendly nasal sprays, and the creation of preservative-free nasal spray options.

The rising prevalence of respiratory diseases is expected to drive the growth of the nasal corticosteroids market in the future. Respiratory diseases involve health conditions affecting the lungs that make breathing difficult, often causing symptoms like coughing or shortness of breath. This increase is largely attributed to worsening air pollution and modern sedentary lifestyles characterized by exposure to harmful pollutants, smoking, and limited physical activity, all of which negatively affect lung health and raise the risk of respiratory issues. Nasal corticosteroids aid in managing respiratory diseases by reducing inflammation in the nasal passages, easing breathing, relieving symptoms such as congestion and sneezing, and improving airflow for greater respiratory comfort. For example, in June 2025, the Office for Health Improvement and Disparities, a UK government department, reported that between the financial years ending 2023 and 2024, emergency admissions for respiratory diseases in England increased by 7%, with specific rises of 9% for COPD, 17% for adult asthma, and 16% for pneumonia. Consequently, the increasing incidence of respiratory diseases is fueling the nasal corticosteroids market growth.

Key companies in the nasal corticosteroids market are focusing on obtaining regulatory approvals for innovative treatments, such as nasal sprays using exhalation delivery systems (EDS), to improve drug delivery efficiency, treatment outcomes, and patient adherence. EDS-based nasal sprays use the patient’s exhaled breath to close the soft palate and deliver medication deep into the nasal passages, enhancing drug deposition in inflamed areas. For instance, in May 2024, Optinose, Inc., a US-based pharmaceutical company, received FDA approval for XHANCE (fluticasone propionate) nasal spray, the first and only medication indicated for adults with chronic rhinosinusitis without nasal polyps (CRSsNP). XHANCE employs a unique EDS technology that delivers corticosteroids deeply into the nasal passages through gentle exhalation, providing targeted anti-inflammatory effects for chronic rhinosinusitis. This approach offers an alternative to conventional nasal sprays, which often have limited reach, by ensuring medication reaches hard-to-access inflamed sites. XHANCE helps alleviate nasal congestion and facial pressure related to chronic rhinosinusitis without nasal polyps and supports long-term management of the condition while avoiding invasive procedures and systemic side effects commonly seen with oral corticosteroids.

In March 2025, Paratek Pharmaceuticals Inc., a US-based biopharmaceutical company, acquired Optinose Inc. for an undisclosed amount. Through this acquisition, Paratek Pharmaceuticals intends to enhance its position in the respiratory and ear, nose, and throat (ENT) therapeutics market and broaden its portfolio with innovative nasal drug delivery products such as Optinose’s XHANCE. Optinose Inc. is a US-based pharmaceutical company specializing in nasal corticosteroids.

Major players in the nasal corticosteroids market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Limited, Cipla Limited, Glenmark Pharmaceuticals Ltd, Alkem Laboratories Ltd, Pharmascience Inc., Mylan N.V., Aspire Pharma (UK), and AdvaCare Pharma.

North America was the largest region in the nasal corticosteroids market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nasal corticosteroids report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the nasal corticosteroids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nasal corticosteroids market includes sales of sprays, inhalers, drops, gels, and ointments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The nasal corticosteroids market research report is one of a series of new reports that provides nasal corticosteroids market statistics, including nasal corticosteroids industry global market size, regional shares, competitors with a nasal corticosteroids market share, nasal corticosteroids market segments, market trends and opportunities, and any further data you may need to thrive in the nasal corticosteroids industry. This nasal corticosteroids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nasal corticosteroids are corticosteroid drugs administered through the nose, usually as nasal sprays, to decrease inflammation within the nasal passages. They are frequently prescribed for conditions like allergic rhinitis, nasal polyps, and chronic sinusitis, helping to alleviate symptoms such as nasal congestion, sneezing, and a runny nose by reducing swelling and irritation of the nasal lining.

The primary types of nasal corticosteroid products include aqueous nasal sprays and non-aqueous nasal sprays. Aqueous nasal sprays are water-based formulations designed to deliver medication directly into the nasal cavities. These products contain various active ingredients such as fluticasone propionate, budesonide, beclomethasone dipropionate, mometasone furoate, triamcinolone acetonide, ciclesonide, among others. They are distributed through multiple channels including hospital pharmacies, retail pharmacies, and online pharmacies, serving applications like allergic rhinitis, nasal polyps, and sinusitis. The end users range from hospitals and clinics to homecare settings.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.